AG 1295

AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor[1][2][3][4].

Product Specifications

CAS Number

[71897-07-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PDGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ag-1295.html

Concentration

10mM

Purity

99.88

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CC1=C(C)C=C2N=CC(C3=CC=CC=C3)=NC2=C1

Molecular Formula

C16H14N2

Molecular Weight

234.30

Precautions

H302, H315, H319, H335

References & Citations

[1]Zheng Y, et al. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Jpn J Ophthalmol. 2003 Mar-Apr;47 (2) :158-65.|[2]Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295. Transplantation. 2002 Nov 15;74 (9) :1335-41.|[3]Kovalenko M, et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 1994 Dec 1;54 (23) :6106-14.|[4]Ludewig D, et al. PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. Cell Tissue Res. 2000 Jan;299 (1) :97-103.